OBJECTIVE: This study aimed to identify the prognostic value of tumor markers in olfactory neuroblastoma (ONB). STUDY DESIGN AND SETTING: Seventeen patients with ONB (23 tumor specimens) were included. Each specimen was studied for bcl-2, p53, MIC-2 by immunohistochemistry and for N-myc by chromogenic in situ hybridization. RESULTS: Twelve (70%) of 17 patients and 15 (65%) of 23 specimens showed positive reactivity for bcl-2. Of seven patients who were treated with neoadjuvant chemotherapy, one patient with diffuse bcl-2 expression achieved complete remission. Another patient without bcl-2 expression had no response to chemotherapy. Five patients who showed partial positivity achieved partial remission. Survival and bcl-2 expression tended to correlate, but it was not statistically significant (P = 0.06). All of the ONB specimens were negative for N-myc. Positive immunoreactivity for MIC-2 or p53 was found only in one specimen. CONCLUSION: Bcl-2 expression was commonly found in ONB and the immunoreactivity for bcl-2 might predict response to neoadjuvant chemotherapy. In addition, Bcl-2 expression tended to be associated with worse survival.
OBJECTIVE: This study aimed to identify the prognostic value of tumor markers in olfactory neuroblastoma (ONB). STUDY DESIGN AND SETTING: Seventeen patients with ONB (23 tumor specimens) were included. Each specimen was studied for bcl-2, p53, MIC-2 by immunohistochemistry and for N-myc by chromogenic in situ hybridization. RESULTS: Twelve (70%) of 17 patients and 15 (65%) of 23 specimens showed positive reactivity for bcl-2. Of seven patients who were treated with neoadjuvant chemotherapy, one patient with diffuse bcl-2 expression achieved complete remission. Another patient without bcl-2 expression had no response to chemotherapy. Five patients who showed partial positivity achieved partial remission. Survival and bcl-2 expression tended to correlate, but it was not statistically significant (P = 0.06). All of the ONB specimens were negative for N-myc. Positive immunoreactivity for MIC-2 or p53 was found only in one specimen. CONCLUSION:Bcl-2 expression was commonly found in ONB and the immunoreactivity for bcl-2 might predict response to neoadjuvant chemotherapy. In addition, Bcl-2 expression tended to be associated with worse survival.
Authors: Ronald Koschny; Heidrun Holland; Jaromir Sykora; Hande Erdal; Wolfgang Krupp; Manfred Bauer; Ulrike Bockmuehl; Peter Ahnert; Jürgen Meixensberger; Wolfgang Stremmel; Henning Walczak; Tom M Ganten Journal: J Neurooncol Date: 2009-09-20 Impact factor: 4.130
Authors: Glen J Weiss; Winnie S Liang; Tyler Izatt; Shilpi Arora; Irene Cherni; Robert N Raju; Galen Hostetter; Ahmet Kurdoglu; Alexis Christoforides; Shripad Sinari; Angela S Baker; Raghu Metpally; Waibhav D Tembe; Lori Phillips; Daniel D Von Hoff; David W Craig; John D Carpten Journal: PLoS One Date: 2012-05-23 Impact factor: 3.240
Authors: Sana D Karam; Ann K Jay; Cynthia Anyanwu; Matthew K Steehler; Bruce Davidson; Pedro Debrito; K William Harter Journal: Front Oncol Date: 2014-03-14 Impact factor: 6.244